Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 2
2017 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Using pharmacogenetics to prevent severe adverse reactions to capecitabine.
García-González X, López-Fernández LA. García-González X, et al. Pharmacogenomics. 2017 Aug;18(13):1199-1213. doi: 10.2217/pgs-2017-0102. Epub 2017 Jul 26. Pharmacogenomics. 2017. PMID: 28746000 No abstract available.
Identification of new SNPs associated with severe toxicity to capecitabine.
Pellicer M, García-González X, García MI, Robles L, Grávalos C, García-Alfonso P, Pachón V, Longo F, Martínez V, Blanco C, Iglesias I, Sanjurjo M, López-Fernández LA. Pellicer M, et al. Pharmacol Res. 2017 Jun;120:133-137. doi: 10.1016/j.phrs.2017.03.021. Epub 2017 Mar 27. Pharmacol Res. 2017. PMID: 28347776
Predicting individual risk of chemotherapy-induced severe adverse reaction is a critical issue when selecting the best treatment for cancer patients. ...The use of tag SNPs to find new polymorphisms related to adverse reactions to capecitabin
Predicting individual risk of chemotherapy-induced severe adverse reaction is a critical issue when selecting the best …
Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Lunenburg CATC, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM, Gelderblom H. Lunenburg CATC, et al. Eur J Cancer. 2016 Feb;54:40-48. doi: 10.1016/j.ejca.2015.11.008. Epub 2015 Dec 21. Eur J Cancer. 2016. PMID: 26716401 Review.
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer drugs. They are inactivated in the liver by the enzyme dihydropyrimidine dehydrogenase (DPD). Up to 5% of the population is DPD deficient and these patients have a significantl …
5-Fluorouracil (5-FU) and capecitabine (CAP) are among the most frequently prescribed anticancer drugs. They are inactivated in the l …
Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients.
Del Re M, Michelucci A, Di Leo A, Cantore M, Bordonaro R, Simi P, Danesi R. Del Re M, et al. EPMA J. 2015 Sep 2;6(1):17. doi: 10.1186/s13167-015-0039-x. eCollection 2015. EPMA J. 2015. PMID: 26330892 Free PMC article.
MATERIALS AND METHODS: We selected three patients with colorectal adenocarcinoma who displayed unexpected severe adverse reactions after treatment with 5-FU and capecitabine. ...CONCLUSIONS: Stratification of patients on the basis of their genotype may …
MATERIALS AND METHODS: We selected three patients with colorectal adenocarcinoma who displayed unexpected severe adverse re
Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D, Cats A, Beijnen JH, Schellens JH. Meulendijks D, et al. Cancer Treat Rev. 2016 Nov;50:23-34. doi: 10.1016/j.ctrv.2016.08.002. Epub 2016 Aug 13. Cancer Treat Rev. 2016. PMID: 27589829 Review.
There is a consistent relationship between DPD activity and 5-FU exposure on the one hand, and risk of severe and potentially lethal fluoropyrimidine-associated toxicity on the other hand. ...Here, we critically review the evidence on clinical validity and utility of strat …
There is a consistent relationship between DPD activity and 5-FU exposure on the one hand, and risk of severe and potentially lethal …
Feedback